Addition of Darolutamide May Augment Standard Treatment for Localized, Very High-Risk Prostate Cancer
January 11th 2021
Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the benefit achieved with standard-of-care radiation therapy plus androgen deprivation therapy with a luteinising hormone-releasing hormone analogue.